Sfoglia per AUTORE
FUSCO V
Collezione AOU Alessandria

  

Items : 26

Medication related osteonecrosis (MRONJ) in the management of CTIBL in breast and prostate cancer patients. Joint report by SIPMO AND SIOMMMS. in Journal of bone oncology / J Bone Oncol. 2024 Dec 16;50:100656. doi: 10.1016/j.jbo.2024.100656. eCollection 2025 Feb.

2025
AOU Alessandria

Guglielmi G; Romeo U; Bedogni A; Palermo A; Pepe J; Mauceri R; Fusco V; Bertoldo F; Eller-Vainicher C; Campisi G;

Italian position paper (SIPMO-SICMF) on medication-related osteonecrosis of the jaw (MRONJ). in Oral diseases / Oral Dis. 2024 Sep;30(6):3679-3709. doi: 10.1111/odi.14887. Epub 2024 Feb 5.

2024
AOU Alessandria

Saia G; Panzarella V; Marchetti C; Lo Casto A; Di Fede O; Bettini G; Bertoldo F; Fusco V; Mauceri R; Bedogni A; Vescovi P; Campisi G;

Oropharyngeal Adverse Events to Drugs and Vaccines: Pharmacovigilance Data From Italy (2019-2021). in Oral diseases / Oral Dis. 2024 Oct 6. doi: 10.1111/odi.15145.

2024
AOU Alessandria

Capuano A; Fusco V; Marrazzo E; Geninatti E; Parrinello G; Zinzi A; Morreale I; Bellavia G; Gaio M; Sottosanti L; Oteri G; Potenza S; Colella G; La Mantia G; Panzarella V; Sportiello L; Campisi G;

Letter to Editor regarding "Why are osteoporosis patients treated with antiresorptive therapies considered like oncology patients regarding their oral health care?". in Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA / Osteoporos Int. 2024 Nov;35(11):2071-2072. doi: 10.1007/s00198-024-07192-4. Epub 2024 Aug 16.

2024
AOU Alessandria

Bertoldo F; Fusco V; Bedogni A; Coppini M; Mauceri R; Campisi G;

Correction: Letter to Editor regarding "Why are osteoporosis patients treated with antiresorptive therapies considered like oncology patients regarding their oral health care?". in Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA / Osteoporos Int. 2024 Nov;35(11):2073. doi: 10.1007/s00198-024-07245-8.

2024
AOU Alessandria

Bertoldo F; Fusco V; Bedogni A; Coppini M; Mauceri R; Campisi G;

Treatment of bone metastases from solid tumors with bone-modifying agents: a web survey of Italian oncologists investigating patterns of practice drug prescription and prevention of side effects. in Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer / Support Care Cancer. 2024 Mar 1;32(3):202. doi: 10.1007/s00520-024-08392-8.

2024
ASL Asti
AOU Alessandria
AO Ordine Mauriziano

Cinieri S; Rossetti G; Airoldi M; Rossi M; Lanzetta G; Cavanna L; Ibrahim T; Bossi P; Santini D; Tucci M; De Giorgi U; Valsecchi AA; Comandone A; Di Maio M; Fusco V;

Management of cancer treatment-induced bone loss in patients with breast and hormone sensitive prostate cancer: AIOM survey. in Tumori / Tumori. 2024 Jun;110(3):174-185. doi: 10.1177/03008916241236279. Epub 2024 Mar 10.

2024
ASL Asti
AOU Alessandria
AO Ordine Mauriziano

Vignani F; Cinieri S; Dionisio R; De Giorgi U; Tucci M; Di Maio M; Santini D; Fusco V; Valsecchi AA;

MRONJ in breast cancer patients under bone modifying agents for cancer treatment-induced bone loss (CTIBL): a multi-hospital-based case series. in BMC oral health / BMC Oral Health. 2023 Feb 4;23(1):71. doi: 10.1186/s12903-023-02732-6.

2023
AOU Alessandria

Oteri G; Leonardi RM; Nisi M; Isola G; Marcianò A; Graziani F; Giudice A; Fusco V; Bettini G; Bedogni A; Attanasio M; Coppini M; Mauceri R; Toro C; Campisi G;

Immune Dysfunction in Medication-Related Osteonecrosis of the Jaw. in International journal of molecular sciences / Int J Mol Sci. 2023 Apr 27;24(9):7948. doi: 10.3390/ijms24097948.

2023
AOU Alessandria

Roato I; Mauceri R; Notaro V; Genova T; Fusco V; Mussano F;

One changing and challenging scenario: the treatment of cancer patients with bone metastases by bisphosphonates and denosumab, the cost-benefit evaluation of different options, and the risk of medication-related osteonecrosis of the jaw (MRONJ). in Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer / Support Care Cancer. 2022 Sep;30(9):7047-7051. doi: 10.1007/s00520-022-06982-y. Epub 2022 Mar 21.

2022
AOU Alessandria

Bedogni A; Campisi G; Fusco V;

Outcomes of the SARS-CoV-2 omicron (B.1.1.529) variant outbreak among vaccinated and unvaccinated patients with cancer in Europe: results from the retrospective, multicentre, OnCovid registry study. in The Lancet. Oncology / Lancet Oncol. 2022 Jul;23(7):865-875. doi: 10.1016/S1470-2045(22)00273-X. Epub 2022 Jun 2.

2022
AOU Alessandria
AOU Novara

Prat A; Rimassa L; Aujayeb A; Queirolo P; Parisi A; Grosso F; Santoro A; Caliman E; Mazzoni F; Giusti R; Zambelli A; Martinez-Vila C; Cantini L; Patriarca A; Bruna R; Ruiz-Camps I; Gaidano G; Fox L; Roldán E; Doonga K; Saoudi-Gonzalez N; Perachino M; Rizzo G; García-Illescas D; Sharkey R; Carmona-García MC; Belessiotis K; Rogers L; Murphy C; et alii...

The preventive care of medication-related osteonecrosis of the jaw (MRONJ): a position paper by Italian experts for dental hygienists. in Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer / Support Care Cancer. 2022 Aug;30(8):6429-6440. doi: 10.1007/s00520-022-06940-8. Epub 2022 Mar 16.

2022
AOU Alessandria

Bertoldo F; Fusco V; Di Fede O; Tomassi D; Panzarella V; Carcieri P; Abbinante A; Coniglio R; Mauceri R; Bedogni A; Campisi G;

Vaccination against SARS-CoV-2 protects from morbidity, mortality and sequelae from COVID19 in patients with cancer. in European journal of cancer (Oxford, England : 1990) / Eur J Cancer. 2022 Aug;171:64-74. doi: 10.1016/j.ejca.2022.04.036. Epub 2022 May 23.

2022
AOU Alessandria
AOU Novara

Parisi A; Delfanti S; Santoro A; Mazzoni F; Filetti M; Berardi R; Martinez-Vila C; Fusco V; Shawe-Taylor M; Patriarca A; Bruna R; Ruiz-Camps I; Gaidano G; Zoratto F; Roldán E; Fox L; Doonga K; Fort-Culillas R; Saoudi-Gonzalez N; Perachino M; Bain HD; Yu T; Cruz CA; Rizzo G; Eremiev S; Sharkey R; Carmona-García MC; Rossi S; Liñan R; et alii...

Is Medication-Related Osteonecrosis of the Jaws (MRONJ) Associated to Cyclin-Dependent Kinase (CDK) 4/6 Inhibitors? A Word of Cautiousness. Comment on Marcianò et al. Medication-Related Osteonecrosis of the Jaws and CDK4/6 Inhibitors: A Recent Association. Int. J. Environ. Res. Public Health 2020, 17, 9509. in International journal of environmental research and public health / Int J Environ Res Public Health. 2021 Sep 27;18(19):10143. doi: 10.3390/ijerph181910143.

2021
ASL Cuneo 2
AOU Alessandria

Rossi M; Fasciolo A; Vincenti M; Guglielmini PF; Alessio M; Fusco V;

A pragmatic window of opportunity to minimise the risk of MRONJ development in individuals with osteoporosis on Denosumab therapy: a hypothesis. in Head & face medicine / Head Face Med. 2021 Jul 9;17(1):25. doi: 10.1186/s13005-021-00280-4.

2021
AOU Alessandria

Fusco V; Bertoldo F; Mauceri R; Campisi G; Bedogni A;

The Treatment of Medication-Related Osteonecrosis of the Jaw (MRONJ): A Systematic Review with a Pooled Analysis of Only Surgery versus Combined Protocols. in International journal of environmental research and public health / Int J Environ Res Public Health. 2021 Aug 10;18(16):8432. doi: 10.3390/ijerph18168432.

2021
AOU Alessandria

Di Fede O; Canepa F; Panzarella V; Mauceri R; Del Gaizo C; Bedogni A; Fusco V; Tozzo P; Pizzo G; Campisi G; Galvano A;

Persistence, compliance, discontinuation rates and switch rates in denosumab and bisphosphonate treatment of bone metastases in cancer patients: reasons of switch, osteonecrosis of the jaw (ONJ) and other critical points. in Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer / Support Care Cancer. 2021 Aug;29(8):4185-4186. doi: 10.1007/s00520-021-06100-4. Epub 2021 Feb 25.

2021
AOU Alessandria

Rossi M; Gambino A; Cabras M; Alessio M; Fusco V;

Adjuvant denosumab in early breast-cancer. in The Lancet. Oncology / Lancet Oncol. 2020 Mar;21(3):e124. doi: 10.1016/S1470-2045(20)30066-8.

2020
AOU Alessandria

Fusco V; Campisi G; Bedogni A; Fusco V; Campisi G; Bedogni A;

Comment on Medication-Related Osteonecrosis of the Jaw: MASCC/ISOO/ASCO Clinical Practice Guideline Summary. in JCO oncology practice / JCO Oncol Pract. 2020 Mar;16(3):142-145. doi: 10.1200/JOP.19.00645. Epub 2020 Jan 24.

2020
AOU Alessandria

Fusco V; Santini D; Campisi G; Bertoldo F; Lanzetta G; Ibrahim T; Bertetto O; Numico G; Addeo A; Berruti A; Bettini G; Saia G; Bedogni A;

Expression levels of circulating miRNAs as biomarkers during multimodal treatment of rectal cancer - TiMiSNAR-mirna: a substudy of the TiMiSNAR Trial (NCT03962088). in Trials / Trials. 2020 Jul 25;21(1):678. doi: 10.1186/s13063-020-04568-9.

2020
AOU Alessandria

Monsellato I; Garibaldi E; Cassinotti E; Baldari L; Boni L; Elmore U; Delpini R; Rosati R; Perinotti R; Alongi F; Bertocchi E; Gori S; Ruffo G; Pernazza G; Pulighe F; De Nisco C; Morpurgo E; Contardo T; Mammano E; Perna F; Menegatti B; Coratti A; Buccianti P; Balestri R; Ceccarelli C; Cavaliere D; Solaini L; Ercolani G; Traverso E; et alii...

Correction to: Standard (8?weeks) vs long (12?weeks) timing to minimally-invasive surgery after NeoAdjuvant Chemoradiotherapy for rectal cancer: a multicenter randomized controlled parallel group trial (TiMiSNAR). in BMC cancer / BMC Cancer. 2020 Feb 17;20(1):128. doi: 10.1186/s12885-020-6632-y.

2020
AOU Alessandria
AOU Novara

Numico G; Franzone P; Priora F; Fusco V; Rossi M; Traverso E; Ercolani G; Cavaliere D; Solaini L; Torri V; Ceccarelli C; Balestri R; Buccianti P; Baroffio P; Gentilli S; Coratti A; Menegatti B; Perna F; Rosati R; Delpini R; Mammano E; Elmore U; Contardo T; Perinotti R; Morpurgo E; De Nisco C; Pulighe F; Pernazza G; Boni L; et alii...

Medication-Related Osteonecrosis of Jaws (MRONJ) Prevention and Diagnosis: Italian Consensus Update 2020. in International journal of environmental research and public health / Int J Environ Res Public Health. 2020 Aug 18;17(16):5998. doi: 10.3390/ijerph17165998.

2020
AOU Alessandria

Campisi G; Mauceri R; Bertoldo F; Bettini G; Biasotto M; Colella G; Consolo U; Di Fede O; Favia G; Fusco V; Gabriele M; Lo Casto A; Lo Muzio L; Marcianò A; Mascitti M; Meleti M; Mignogna MD; Oteri G; Panzarella V; Romeo U; Santarelli A; Vescovi P; Marchetti C; Bedogni A;

Standard (8?weeks) vs long (12?weeks) timing to minimally-invasive surgery after NeoAdjuvant Chemoradiotherapy for rectal cancer: a multicenter randomized controlled parallel group trial (TiMiSNAR). in BMC cancer / BMC Cancer. 2019 Dec 16;19(1):1215. doi: 10.1186/s12885-019-6271-3.

2019
AOU Alessandria
AOU Novara

Numico G; Franzone P; Priora F; Fusco V; Rossi M; Traverso E; Ercolani G; Cavaliere D; Solaini L; Torri V; Ceccarelli C; Balestri R; Buccianti P; Baroffio P; Gentilli S; Coratti A; Menegatti B; Perna F; Rosati R; Delpini R; Mammano E; Elmore U; Contardo T; Perinotti R; Morpurgo E; De Nisco C; Pulighe F; Pernazza G; Boni L; et alii...

Osteonecrosis of the Jaw in Myeloma Patients Receiving Denosumab or Zoledronic Acid. A Commentary of the Pivotal Trial by Raje et al. Published on Lancet Oncology. in Dentistry journal / Dent J (Basel). 2018 Sep 1;6(3):42. doi: 10.3390/dj6030042.

2018
AOU Alessandria

Fusco V; Campisi G; de Boissieu P; Monaco F; Baraldi A; Numico G; Bedogni A;

Incidence of osteonecrosis of the jaw (ONJ) in cancer patients with bone metastases treated with bisphosphonates and/or denosumab: some comments and questions. in Acta clinica Belgica / Acta Clin Belg. 2018 Apr;73(2):163-164. doi: 10.1080/17843286.2017.1389473. Epub 2017 Nov 7.

2018
AOU Alessandria

Fusco V; Rossi M; De Martino I; Alessio M; Fasciolo A; Numico G;

The Dental Management of Patients at Risk of Medication-Related Osteonecrosis of the Jaw: New Paradigm of Primary Prevention. in BioMed research international / Biomed Res Int. 2018 Sep 16;2018:2684924. doi: 10.1155/2018/2684924. eCollection 2018.

2018
AOU Alessandria

Di Fede O; Panzarella V; Mauceri R; Fusco V; Bedogni A; Lo Muzio L; Sipmo Onj Board; Campisi G;